Before prescribing Semaglutide GLP-1 treatment, your healthcare provider will carefully consider several aspects of your medical history
Specifically developed for oral use
Speaking at the launch, Vikrant Shrotriya, Corporate Vice President and Managing Director, Novo Nordisk India, said Oral semaglutide has a strong clinical profile, we believe, it has the potential to revolutionise the treatment of type 2 diabetes, given that millions of people do not achieve the targeted blood sugar levels with currently available oral antidiabetic medications.Likewise, we believe, semaglutide in oral form will transform the management of diabetes demonstrating our dedication to advancing patient care through continued innovation. Dr Shashank Joshi, Chair IDF Southeast Asia and Consultant Endocrinologist at Lilavati Hospital, Bhatia Hospital and Joshi Clinic, Mumbai said, "Glucagon-like peptide 1 (GLP-1) is a naturally occurring hormone and plays an important role in maintaining the normal level of glucose in the blood
Caffeine and liquor are diuretics which increase urination causing dehydration
Glucose markers if also using glucose-lowering medications
